Birt–Hogg–Dubé syndrome with rare unclassified renal cell carcinoma
A case report
Shangqing Ren, MD\textsuperscript{a,c}, Cheng Luo, MS\textsuperscript{a}, Yaoqian Wang, MS\textsuperscript{a}, Yi Wei, MS\textsuperscript{a}, Yong Ou, MS\textsuperscript{a}, Jiazheng Yuan, MS\textsuperscript{a}, Xinglan Li, MD\textsuperscript{b,c}, Junyao Wang\textsuperscript{b}, Qian Lv, MS\textsuperscript{a}, Bo Yang, MD\textsuperscript{d}, Shida Fan, MS\textsuperscript{a}, Fang Zhou, MD\textsuperscript{a}, Zhengjun Chen, MS\textsuperscript{a}, Yu Nie, MS\textsuperscript{a}, Dong Wang, MS\textsuperscript{a,c}.\textsuperscript{*}

Abstract
Introduction: Birt-Hogg-Dubé syndrome (BHDS) is a rare genetic disease. Renal cell carcinoma is the most serious complication of BHDS. The histological types of BHDS-related renal cell carcinoma are mostly mixed chromophobe/eosinophil and chromophobe cell types. BHDS with unclassified renal cell carcinoma is extremely rare.

Patient concerns: A 37-year-old man was admitted to the hospital because of lumbago and hematuria.

Diagnosis: Combined with abdominal enhanced CT and pulmonary CT, BHDS complicated with renal cell carcinoma was diagnosed, and right partial nephrectomy was performed. The postoperative pathological diagnosis was unclassified renal cell carcinoma. Gene detection revealed the FLCN frameshift mutation.

Outcomes: No signs of recurrence were observed after regular follow-up.

Conclusion: The pathogenesis of BHDS has not been fully elucidated, and the pathological type of BHDS with unclassified renal cell carcinoma is extremely rare. Through case presentation and review of related literature, this paper summarizes the diagnosis and treatment of BHDS complicated with unclassified renal cell carcinoma.

Abbreviations: BHDS = Birt-Hogg-Dubé syndrome, CT = computerized tomography, FLCN = folliculin, FNIP1 = Folliculin-interacting protein1, FNIP2 = Folliculin-interacting protein2, mTOR = mechanistic target of rapamycin, RCC = renal cell carcinoma.

Keywords: Birt-Hogg-Dubé syndrome, case report, renal cell carcinoma, unclassified renal cell carcinoma

Editor: Maya Saranathan.
SR and CL contributed equally.
This study was supported by the Universal Application Project of Sichuan Provincial Health and Family Planning Commission of China (serial number 16PJ490) and \textsuperscript{*}the General Item of Medical Engineering Cross-linked Foundation-Innovative Foundation (serial number ZYDQ2021YGLH011) of Sichuan Provincial People’s Medical Hospital, University of Electronic Science and Technology of China.
The case involves only an objective retrospective description; therefore, it is not applicable to ethics approval. The patient provided consent for the use of physical and imaging information from the patient.
Written informed consent was obtained from the patient’s next of kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
All the data and material were obtained from the patient’s assay and examination of the Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, which are real, credible, and available.
The authors declare that they have no competing interests.
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
\textsuperscript{a} Department of Robotic Minimally Invasive Surgery Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China, \textsuperscript{b} Department of Pathology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China, \textsuperscript{c} Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China, \textsuperscript{d} Department of Pediatric Surgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China.

Correspondence: Dong Wang, Department of Robotic Minimally Invasive Surgery Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, No. 32 West Second Section First Ring Road, Chengdu, Sichuan 610072, China (e-mail: wangdong_robot#163.com).
Copyright \textcopyright{} 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite this article: Ren S, Luo C, Wang Y, Wei Y, Ou Y, Yuan J, Li X, Wang J, Lv Q, Yang B, Fan S, Zhou F, Chen Z, Nie Y, Wang D. Birt–Hogg–Dubé syndrome with rare unclassified renal cell carcinoma: A case report. Medicine 2021;100:51(e28380).
Received: 16 November 2021 / Accepted: 2 December 2021
http://dx.doi.org/10.1097/MD.00000000000028380
1. Introduction

Birt-Hogg-Dubé syndrome (BHDS) is an autosomal dominant hereditary disease associated with folliculin (FLCN) gene mutation on chromosome 17. It was first reported and named by Birt et al in 1993, but its pathogenesis has not been fully elucidated. The main clinical manifestations of the disease are benign tumors of the skin, cystic changes in the lungs, and various types of renal tumors. Among them, renal cell carcinoma (RCC) is the most serious complication of BHDS, which often occurs in multifocal or bilateral cases. Most of them have slow growth, low invasiveness, and occasional metastasis. There are various tissue types of BHDS-related RCC, and multiple tumors in the same patient may present different pathological types, with more mixed chromophobe/oncocytomas and chromophobe cell types, and fewer clear cell and papillary RCC types. As the World Health Organization (WHO) updated the pathological classification of renal tumors in 2016, there have been no cases of BHDS with unclassified RCC. Surgery is the main treatment for BHDS complicated with RCC, and it has also been reported that the mechanistic target of rapamycin (mTOR) inhibitor everolimus can be used in the treatment of metastatic RCC, but its efficacy evaluation requires further research.

2. Case presentation

A male, 37 years old, was admitted to the hospital in September 2020 because of bilateral lumbago for 6 days and aggravation with hematuria for 2 days. He had a previous medical history of spontaneous pneumothorax, and his father had a history of spontaneous pneumothorax. Color Doppler ultrasound of the urinary system showed a slightly hyperechoic mass of approximately $53 \times 37 \times 31$ mm in size was detected in the middle part of the right kidney, protruding to the outside of the capsule, and the internal echo was non-homogeneous and the blood flow signal could be seen. Contrast-enhanced computed tomography (CT) of the whole abdomen (Fig. 1) suggested that there was a quasi-circular, slightly high-density mass in the lower part of the right kidney, with calcification in the lower part of the right kidney, with a maximum diameter of approximately 39 mm, protruding the outline of the kidney and showing obvious inhomogeneous enhancement in the arterial phase. Plain chest CT (Fig. 2) showed that multiple cystic low-density shadows in both lungs were irregular in size, mainly in the lower part, subpleural, and adjacent to the interlobar fissure, with a maximum diameter of approximately 13.6 mm. Robot-assisted laparoscopic partial nephrectomy was performed under general anesthesia on September 15, 2020. During the operation, a $40 \times 40 \times 30$ mm mass was observed on the dorsal side of the middle and inferior pole of the right kidney, part of which was endogenetic; the boundary was unclear, and fish-like new organisms and scattered necrotic hemorrhagic foci could be seen in the specimen profile. Postoperative pathological diagnosis (Fig. 3) revealed that the maximum diameter of the tumor was approximately 55 mm, and there was no tumor infiltration at the cutting edge of the specimen. Combined with morphology, immunophenotype, and related gene detection, it was considered as unclassified RCC. Among them, the postoperative gene detection showed that the gene FLCN frameshift mutation, the mutation result c. 946–947del (p.s316fs), had an abundance of 54.49%. Regular follow-up was performed every 3 months after discharge, and the recovery was very good, and abdominal CT (Fig. 4) showed no obvious signs of recurrence.
3. Discussion

BHDS is an autosomal dominant genetic disease characterized by benign skin tumors, cystic changes in the lungs, and various types of renal tumors. Pulmonary cystic change, which is observed in 90% of patients, is the most common manifestation of BHDS. It is usually irregular, mostly at the base of the lung, rarely at the tip of the lung, and varies in number and size. Kumasaka et al. believe that the loss of FLCN leads to the weakening of the alveolar wall, which is easily destroyed by mechanical pressure during respiration, which leads to cystic changes. This paper reports a history of pneumothorax, combined with his father’s history of spontaneous pneumothorax, consistent with the characteristics of the genetic diagnosis.

RCC is the most serious complication of BHDS, usually bilateral or multiple, with slow growth, low invasiveness, and occasional metastasis. The incidence in BHDS patients is approximately 30%, and the risk of kidney cancer is approximately seven times higher than that in the general population. BHDS-related renal tumors are histologically diverse. A study analyzed the histology of 130 renal tumors removed from 30 BHDS patients and found that 50% were mixed chromophobe/oncocytomas, 34% were chromophobe cells, 9% were clear cells, 5% were oncocytomas, and 2% were papilloma. In addition, many studies have also reported that the pathological type of BHDS complicated with RCC is mixed chromophobe/oncocytomas, and chromophobe cells are common. Over the past few decades, due to the in-depth study of genetics and morphology and more accurate detection instruments, the classification of RCC has experienced continuous improvement. The WHO first introduced the concept of unclassified RCC in 1997, and RCC that did not belong to the four common types known at that time were classified into this category. In 2004, the WHO further specified the characteristics of this type of RCC: a mixture of known types of RCC, pure sarcomatoid morphology without recognizable epithelial components, mucin production, a rare mixture of epithelial and matrix components, and unrecognizable cell types. In 2016, the WHO released the latest classification of RCC, including 6 new subtypes of RCC and four provisional subtypes of RCC, further narrowing the scope of unclassified RCC.

FLCN gene detection is the most significant diagnostic method for BHDS. This patient was also definitively diagnosed with the results of a gene test for FLCN abnormalities. Fibrofollicular tumor or trichodiscoma diagnosed by skin pathological biopsy is another major criterion for the diagnosis of BHDS. The diagnosis of BHDS-related pulmonary cysts usually depends on CT, and high-resolution CT is recommended for differentiation from other cystic lung diseases. It is recommended that the monitoring age of BHDS-related renal cell carcinoma should start from 20 years of age, and CT and MRI are recommended. However, because of the long surveillance period of the disease, repeated CT may produce an unacceptably high cumulative radiation dose, so MRI seems to be the best surveillance method. In addition, clinical symptoms and family genetic history are still very important in the diagnosis of BHDS.

At present, there is no cure for BHDS, and the treatment of pneumothorax is the same as that in ordinary pneumothorax patients; for patients with recurrent pneumothorax, pleural adhesion can be considered to reduce the risk of recurrent pneumothorax. The degree of malignancy and invasiveness of
most BHDS-related renal tumors are relatively low, but the recurrence rate is high and often multiples. For long-term preservation of renal function, surgical resection should be conservative and cautious. Follow-up observation or percutaneous thermal ablation is usually recommended for renal tumors measuring < 3 cm. Nephron-sparing partial nephrectomy is preferred for renal tumors measuring > 3 cm.[3]

The pathogenic genes FLCN and its 2 proteins FNIP1 (Folliculin-interactingprotein1) and FNIP2 (Folliculin-interacting protein2) play a synergistic role in metabolic pathways, including AMPK-mediated energy sensing, mTORC1-dependent cell proliferation, and Ppargc1a-driven mitochondrial oxidation, and disorders in these metabolic pathways trigger abnormal renal cell proliferation and renal tumorigenesis.[14] Further studies on FLCN function, such as targeted therapy with mTOR inhibitors for BHDS-related renal cell carcinoma have been reported.[13]

The National Institutes of Health recently announced a new clinical trial on the use of the mTOR inhibitor everolimus in the treatment of patients with RCC. Everolimus has been approved for the treatment of sporadic metastatic RCC, but it has not been specifically tested in BHDS-related and sporadic chromophobe cell RCC. Cases of BHDS complicated with unclassified RCC are extremely rare and require multidisciplinary cooperation to develop individualized treatment. At present, surgical resection is still the main method, and mTOR inhibitors can be used if necessary, but the clinical efficacy remains to be reported and prospectively studied in more cases of BHDS with unclassified RCC.

4. Conclusion

BHDS is a rare genetic disease. FLCN is the only related gene known to date, and its pathogenesis has not been fully elucidated. RCC is bilateral or multiple, the pathological type is mixed chromophobe/oncocytomas, chromophobe cells are common, and the pathological type of undifferentiated RCC BHDS is extremely rare and requires multidisciplinary cooperation to develop individualized treatment, still dominated by surgical treatment. Clinically, early diagnosis, early treatment, and long-term follow-up are the primary methods. The choice of examination and follow-up methods can be individualized. In terms of lifestyle, patients with pneumothorax should avoid diving, flying, and strenuous exercise as far as possible.

Acknowledgments

The authors would like to express my gratitude to Dr Wang Dong, who provided me with valuable guidance for this article.

Author contributions

SQR and CL were responsible for writing and editing the article; YQW, YW, YO, and JZY were responsible for reviewing the literature; XLL, YJW, QL, BY, SDF, FZ, ZJC, and YN were responsible for collecting the information of the current case. DW was responsible for revising the manuscript for important intellectual content. All authors have read and approved the manuscript.

Data curation: Shangqing Ren, Cheng Luo, Yaoqian Wang, Yi Wei, Yong Ou, Jiazheng Yuan, Xinglan Li, Junyao Wang, Qian Lv, Bo Yang, Shida Fan, Fang Zhou, Zhengjun Chen, Yu Nie.

Investigation: Shangqing Ren, Cheng Luo, Yaoqian Wang, Yi Wei, Yong Ou, Jiazheng Yuan.

Project administration: Dong Wang.

Writing – original draft: Cheng Luo.

Writing – review & editing: Shangqing Ren, Cheng Luo, Dong Wang.

References

[1] Guo J, Huang Y, Zhang X, et al. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study. BMC Cancer 2013;13:136.
[2] Motzer RJ, Escudier B, Oudard S, et al. RECORD-1 Study GroupPhase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256–65.
[3] Steinlein OK, Ertl-Wagner B, Ruzicka T, Sattler EC. Birt-Hogg-Dubé syndrome: an underdiagnosed genetic tumor syndrome. J Dtsch Dermatol Ges 2018;16:278–83.
[4] Kuroda N, Furuya M, Nagashima Y, et al. Review of renal tumors associated with Birt-Hogg-Dubé syndrome with focus on clinical and pathobiological aspects. Polish J Pathol 2014;65:93–9.
[5] Menko FH, van Steensel MA, Giraud S, et al. European BHD ConsortiumBirt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol 2009;10:1199–206.
[6] Kumasaka T, Hayashi T, Mitani K, et al. Characterization of pulmonary cysts in Birt-Hogg-Dubé syndrome: histopathological and morphometric analysis of 229 pulmonary cysts from 50 unrelated patients. Histopathology 2014;65:100–10.
[7] Daccord C, Good JM, Morren MA, et al. Birt-Hogg-Dubé syndrome. Eur Respir Rev 2020;29:200042.
[8] Gupta S, Kang HC, Ganeshan D, et al. The ABCs of BHD: an in-depth review of Birt-Hogg-Dubé syndrome. AJR Am J Roentgenol 2017;209:1291–6.
[9] Sirohi D, Smith SC, Agarwal N, Maughan BL. Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. Res Rep Urol 2018;10:205–17.
[10] Akgul M, Cheng L. Immunophenotypic and pathologic heterogeneity of unclassified renal cell carcinoma: a study of 300 cases. Human pathology 2020;102:70–8.
[11] Lopez-Beltran A, Kirkali Z, Montironi R, et al. Unclassified renal cell carcinoma: a report of 56 cases. BJU international 2012;110:786–93.
[12] Cornelis FH, Bernhard JC. Diagnostic and interventional radiology is a milestone in the management of renal tumors in Birt-Hugg-Dubé syndrome. Diagn Interv Imaging 2019;100:657–8.
[13] Johannesma PC, van de Beek L, van der Wel T, et al. Renal imaging in 199 Dutch patients with Birt-Hogg-Dubé syndrome: screening compliance and outcome. PLoS One 2019;14:e0212952.
[14] Hasumi H, Baba M, Hasumi Y, et al. Birt-Hogg-Dubé syndrome: clinical and molecular aspects of recently identified kidney cancer syndrome. Int J Urol 2016;23:204–10.
[15] Nakamura M, Yao M, Sano F, et al. Hinyokika kiyo. Acta Urol Japon 2013;59:503–6.